CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced an agreement has been reached with its secured lender Hercules Technology III, L.P., an affiliate of Hercules Capital (NYSE: HTCG), for the use of cash collateral through July 8, 2016 subject to certain agreed upon terms and conditions. As part of the agreement negotiated under BIND’s voluntary chapter 11 filing, t
![]()
↧